Ikobel (Tobramycin)

Ikobel (tobramycin) is an aminoglycoside antibiotic formulated for ophthalmic use, employed to treat a range of bacterial infections affecting the eye's surface and cornea.

• Bacterial conjunctivitis: reduces bacterial load, alleviates redness and discharge, and promotes rapid resolution of infection.
• Keratitis: eradicates causative Gram‑negative organisms, limiting corneal inflammation and preventing stromal damage.
• Corneal ulcer: penetrates ulcerated tissue to eliminate infection, supporting re‑epithelialisation and visual recovery.
• Post‑operative ocular infection: applied prophylactically to reduce risk of bacterial colonisation after eye surgery.
• Bacterial blepharitis: helps control infection of eyelid margins.

• Tobramycin binds to the 30S subunit of bacterial ribosomes, causing misreading of mRNA and inhibiting initiation of protein synthesis. This disruption leads to rapid bactericidal activity against susceptible Gram‑negative organisms, including Pseudomonas aeruginosa, by preventing the formation of essential proteins required for bacterial growth and survival. The drug’s high affinity for bacterial ribosomal RNA ensures selective toxicity, while minimal systemic absorption from ocular administration limits systemic effects.

Topical tobramycin may cause ocular discomfort and, in rare cases, more severe reactions.

Common Side Effects

• Eye irritation: transient burning, stinging or itching sensation that usually resolves after continued use.
• Redness: mild conjunctival hyperemia causing the eye to appear pink.
• Tearing: increased lacrimation leading to watery eyes during treatment.
• Blurred vision: temporary visual disturbance that clears once the drop is absorbed.

Serious or Rare Side Effects

• Allergic reaction: swelling of the eyelid, itching, rash or hives that may require immediate discontinuation and medical attention.
• Corneal ulcer worsening: progression of the ulcer or development of a new ulcer despite therapy, indicating possible resistance.
• Systemic toxicity: rare systemic absorption leading to nephrotoxicity or ototoxicity, especially in patients with renal impairment.

When using Ikobel, certain precautions help ensure safety and effectiveness.

• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown excretion in milk; consider alternative therapy or monitor infant.
• Renal impairment: monitor for systemic absorption and adjust therapy as needed.
• Contact lens wearers: avoid wearing lenses until treatment is completed and the eye is clear.
• Allergy: discontinue immediately if signs of hypersensitivity such as swelling or rash appear.
• Store below 25°C: keep in original container, protect from light and moisture.

Tobramycin may interact with other medicines, affecting its safety profile.

Major Interactions (Avoid)

• Nephrotoxic drugs (e.g., aminoglycosides, vancomycin): increased risk of kidney toxicity.
• Loop diuretics (e.g., furosemide): heightened nephrotoxicity when combined.
• Neuromuscular blocking agents: may potentiate neuromuscular blockade leading to respiratory weakness.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: can mask infection signs and reduce antibiotic efficacy.
• Other ophthalmic antibiotics: potential antagonism or additive toxicity.
• Systemic aminoglycosides: cumulative exposure may increase systemic toxicity.
• Anticholinergic eye drops: may affect tear film and drug distribution.